Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't ...

Intellia Therapeutics (NTLA) stock fell ~9% in reaction to Phase 2 trial data for a CRISPR-based gene editing therapy for ...

Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...

Based on these findings, Intellia chose the 50 mg dose for their Phase 3 research, HAELO, which is now under enrollment ...

JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on NTLA stock, giving a Buy rating on October 16. Debanjana ...

Intellia Therapeutics (NTLA) announced positive Phase 2 data from the ongoing Phase 1/2 study of NTLA-2002 in patients with hereditary ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $17.5 to $20.0 for Intellia Therapeutics over the recent three months.

Intellia Therapeutics' Phase 2 data shows NTLA-2002, a CRISPR gene therapy, reduced hereditary angioedema attack rates by up to 81%, with complete responses.

Biotech stocks Viking Therapeutics (VKTX) and Intellia Therapeutics (NTLA are both making outsized moves today ...

Poseida Therapeutics’ gene therapy for hereditary angioedema (HAE) reduced kallikrein protein activity in a mouse model of ...

We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...

For adults with hereditary angioedema, the in vivo gene-editing therapy NTLA-2002, which is based on clustered regul ...